NCT00742963 2025-05-13
Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma
ImmunoGenesis
Phase 1/2 Completed
Clinical Trials
8 trialsNCT01746979 2025-05-11
MAESTRO
ImmunoGenesis
Phase 3 Completed
NCT01864538 2025-05-11
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
ImmunoGenesis
Phase 2 Terminated
NCT02047500 2025-05-11
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
ImmunoGenesis
Phase 1 Terminated
NCT02342379 2020-04-10
TH-302 in Combination With Bevacizumab for Glioblastoma
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT01403610 2019-07-24
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT02255110 2018-12-14
A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Merck KGaA, Darmstadt, Germany
Phase 2 Terminated
NCT01833546 2018-10-15
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Merck KGaA, Darmstadt, Germany
Phase 1 Completed